Image Source: AsiaOne
Athenex Pharmaceutical Division and Ingenus Pharmaceuticals Announce Availability of Liquid, Ready to Dilute CyclophosphamideGlobeNewswireDecember 02, 2020BUFFALO, N.Y., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that its subsidiary, Athenex Pharmaceutical Division (APD), has launched Liquid, Ready-To-Dilute Cyclophosphamide. The product is being brought to market through APD’s co-marketing partnership with Ingenus Pharmaceuticals, LLC. APD will leverage existing commercial relationships with hospitals, integrated health systems, which include U.S. cancer centers, major distributors, and GPOs, to optimize distribution and commercial uptake of Liquid, Ready-To-Dilute Cyclophosphamide.
Source: AsiaOne